Oncodesign, Sanofi Sign Second Kinase Inhibitor Pact

Oncodesign, a provider of pharmacological evaluation services, has entered its second research collaboration agreement with Sanofi relating to several kinase targets being developed by Sanofi.  This second agreement aims to identify inhibitors of a kinase that plays a key role in tissue protection and repair. Financial details were not disclosed.
 
Oncodesign will use its Nanocyclix technology to design and synthesize potent new selective inhibitors. Sanofi will be responsible for the cost of the initial phase of the work and will have exclusive licensing rights to the molecules that result from the collaboration.
 
“This new agreement with Sanofi demonstrates the level of interest in our Nanocyclix technology from some of the most well-renowned pharma companies. This is our third collaboration agreement in a year of drug discovery, establishing our company as a leader in the field of kinase inhibitors in a variety of therapeutic areas,” said Dr. Philippe Genne, chairman, chief executive officer and founder of Oncodesign.